>
Switch to:

ORIC Pharmaceuticals EV-to-EBIT

: -4.86 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ORIC Pharmaceuticals's Enterprise Value is $323.63 Mil. ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-66.65 Mil. Therefore, ORIC Pharmaceuticals's EV-to-EBIT for today is -4.86.

The historical rank and industry rank for ORIC Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

NAS:ORIC' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.25   Med: 0   Max: 0
Current: -4.92

-13.25
0
NAS:ORIC's EV-to-EBIT is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 21.16 vs. NAS:ORIC: -4.92 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ORIC Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2021 was $390.04 Mil. ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-66.65 Mil. ORIC Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -17.09%.


ORIC Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for ORIC Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20
EV-to-EBIT
- - -19.21

ORIC Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.47 -13.84 -19.21 -10.98 -5.85

Competitive Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ORIC Pharmaceuticals EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's EV-to-EBIT falls into.



ORIC Pharmaceuticals EV-to-EBIT Calculation

ORIC Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=323.627/-66.651
=-4.86

ORIC Pharmaceuticals's current Enterprise Value is $323.63 Mil.
ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ORIC Pharmaceuticals  (NAS:ORIC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ORIC Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=-66.651/390.044964
=-17.09 %

ORIC Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2021 was $390.04 Mil.
ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ORIC Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

ORIC Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533.
Executives
Kunkel Lori Anne director C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Chacko Jacob director, officer: President and CEO C/O IGNYTA, INC. 11095 FLINTKOTE AVE., SUITE D SAN DIEGO CA 92121
Topspin Biotech Fund Ii, L.p. 10 percent owner 3 EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Lg Management, Llc 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Topspin Fund L.p. 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Heyman Richard A. director 5871 OBERLIN DRIVE, SUITE 150 SAN DIEGO CA 92121
Scheller Richard H director C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990
Guthart Leo 10 percent owner C/O APTUR GROUP INC 475 W TERRA COTTA AVE STE E CRYSTAL LAKE IL 60014
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Goeddel David V 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Svennilson Peter director, 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Gordon Carl L director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)